Diabetes & metabolic syndrome | 2021
Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients having reduced ejection fraction heart failure with type 2 diabetes, prediabetes and normoglycemia?
Abstract
BACKGROUND AND AIMS\nWe aimed to know whether SGLT-2 inhibitors (SGLT-2I) exhibit similar cardiovascular (CV) benefit in patients having reduced ejection fraction heart failure (HFrEF) with varying degree of glycemia.\n\n\nMETHOD\nWe meta-analyzed the trial-level hazard ratio and 95% confidence interval of randomized trials that reported the CV outcomes stratified in to three subgroups of normoglycemia, prediabetes and diabetes.\n\n\nRESULTS\nThis meta-analysis found a significant and similar CV risk reduction in patients with HFrEF without any significant interaction between three subgroups (PIntercation\xa0=\xa00.98).\n\n\nCONCLUSIONS\nSGLT-2I exhibit similar CV risk reduction in HFrEF, regardless of baseline glycemic status. However, this finding is limited to pooled data from only 2 studies in people without T2DM.